重症肌无力多病共存患者高风险药物识别与靶向治疗进展OA

Myasthenia gravis(MG)is an autoimmune disease mediated by autoantibodies and involved in neuromuscular junction(NMJ)transmission.Elderly MG patients are often complicated with multiple diseases,bringing severe challenges to clinical polypharmacy management.Starting with the medication risks of one elderly MG patient with multimorbidity,this article systematically summarizes the identification of high-risk drugs and related medication suggestions for MG patients with multiple diseases,and analyzes the combined medication risks of traditional MG drugs such as cholinesterase inhibitors,glucocorticoids and immunosuppressants.In view of the clinical dilemma of insufficient specificity and high combined medication risk of traditional MG regimens,this paper further expounds the mechanism of action,applicable population,administration route,safety characteristics and drug interaction of three targeted biological agents including efgartigimod,eculizumab and telitacicept,so as to achieve the dual goals of stable disease control and medication safety,and improve the long-term quality of life of patients.